PRV211 (Intraoperative Cisplatin System)
Phase 3Small molecule
PRV211 (Intraoperative Cisplatin System) is one of 14 small molecule programs targeting Oral Squamous Cell Carcinoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Oral Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Aldara
BBausch Health Americas, Inc.
Approved
Glucophage
EMD SeronoApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Beyfortus
BeiGenePhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Flagyl
DDePuy Orthopaedics
Phase 2
Becotatug Vedotin
FFudan University
Phase 2
Pucotenlimab
SSun Yat-sen University
Phase 2
Albumin Paclitaxel
CChipscreen Biosciences, Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPrivo Technologies